Change in biomarker levels between sample 1 (pre-TNFi treatment) and sample 2 (on TNFi treatment).
| Biomarker | Pre-TNFi Treatment | On TNFi Treatment | p |
|---|---|---|---|
| hsCRP, mg/l | 6.8 (3.8) | 2.0 (2.1) | < 0.001 |
| MMP-3, ng/ml | 31.8 (21.8) | 19 (9.3) | 0.001 |
| RANKL, pg/l | 301.2 (153.3) | 376.4 (199.3) | 0.062 |
| OPG, pg/ml | 626.2 (145.5) | 625.7 (183.2) | 0.988 |
| RANKL:OPG | 0.52 (0.32) | 0.70 (0.52) | 0.063 |
| TNFSF14, pg/ml | 217.2 (172.0) | 219 (127.6) | 0.958 |
| C2C, ng/ml | 167.8 (44.6) | 190.2 (54.3) | 0.048 |
| C1-2C, μg/ml | 0.2 (0.1) | 0.3 (0.1) | 0.469 |
| CPII, ng/ml | 407.8 (345.7) | 394.2 (297.9) | 0.851 |
| CPII:C2C | 2.35 (1.62) | 2.04 (1.04) | 0.317 |
| CS-846, ng/ml | 101 (36.1) | 98.4 (42.7) | 0.766 |
| COMP, ng/ml | 1044.7 (471.2) | 1060.4 (438.9) | 0.878 |
TNFi: tumor necrosis factor inhibitor; COMP: cartilage oligomeric matrix protein; hsCRP: highly sensitive C-reactive protein; RANKL: receptor activator of nuclear factor κ-B ligand; OPG: osteoprotegerin; RANKL:OPG: ratio of RANKL to OPG; TNFSF14: TNF super family member 14; MMP-3: matrix metalloproteinase-3; CS-846: aggrecan chondroitin sulfate 846 epitope; C1-2C: Col2-3/4Cshort; CPII: C-propeptide of type II collagen; C2C: Col2-3/4Clong mono; CPII:C2C: ratio of CPII to C2C.